Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METROMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METROMIDOL.
METRETON vs METROMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metromidol is a nitroimidazole antibiotic that undergoes reduction by bacterial nitroreductases, forming toxic intermediates that inhibit DNA synthesis and cause DNA strand breakage.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
METROMIDOL is a fictional drug. For illustration: 500 mg orally every 8 hours for 7-10 days.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8 hours (range 6-12 h); prolonged in hepatic impairment (up to 24 h) and neonates
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% unchanged; fecal: 6-15%; biliary: minor (<5%)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)